KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) EBIT Margin (2023 - 2025)

Biocryst Pharmaceuticals' EBIT Margin history spans 9 years, with the latest figure at 36777.54% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 3678097.0% year-over-year to 36777.54%; the TTM value through Dec 2025 reached 72.71%, up 7327.0%, while the annual FY2025 figure was 38.98%, 3954.0% up from the prior year.
  • EBIT Margin reached 36777.54% in Q4 2025 per BCRX's latest filing, up from 18.56% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 36777.54% in Q4 2025 to a low of 25.05% in Q4 2023.
  • Average EBIT Margin over 3 years is 4088.82%, with a median of 8.01% recorded in 2024.
  • The largest YoY upside for EBIT Margin was 3678097bps in 2025 against a maximum downside of 1022bps in 2025.
  • A 3-year view of EBIT Margin shows it stood at 25.05% in 2023, then skyrocketed by 86bps to 3.43% in 2024, then soared by 1073192bps to 36777.54% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's EBIT Margin are 36777.54% (Q4 2025), 18.56% (Q3 2025), and 18.23% (Q2 2025).